
LONDON — The board of AstraZeneca on Monday rejected the improved $119 billion takeover offer from US drug maker Pfizer, a decision that caused a sharp slide in the UK company’s share price. Many investors think it effectively brings an end to the protracted and increasingly bitter takeover saga.

Pfizer, the world’s second-biggest drug maker by revenue, has been courting number eight AstraZeneca since January, saying their businesses are complementary.

On Sunday, it raised its stock-and-cash offer by 15 percent to $118.8 billion.

That would be the richest acquisition ever among drug makers and the third-biggest in any industry, according to Dealogic.

AstraZeneca did not take long to reject the new offer, its board arguing that Pfizer is making ‘‘an opportunistic attempt to acquire a transformed AstraZeneca, without reflecting the value of its exciting pipeline’’ of experimental drugs.

You can now read 10 free articles.

Read it all, now.

Don't miss any of your favorite stories again. Read the stories that matter to you as much as you want, whenever you want when you subscribe to BostonGlobe.com.

The login information you entered does not match an account in our records.

To activate FREE access as a home delivery subscriber start here.

If you don't have a subscription, you can view our digital offers here.

Please check your e-mail for a message from BostonGlobe.com with the subject line "BostonGlobe.com password request." Click the link in the e-mail to choose a new password for BostonGlobe.com, and note that your new password will also be used for your Boston.com membership.

Enter your e-mail address below. We’ll send you an e-mail with a link to reset your password.

Continue reading by subscribing to BostonGlobe.com for just 99¢ .

Continue reading by subscribing to BostonGlobe.com for just 99¢ .

Stay informed with unlimited access to Boston’s trusted news source.
